Physician's Choice

DRUG10 trials

Conditions

Advanced Solid TumorBRAF Gene AlterationBRAF Gene MutationBRCA1 Gene MutationBRCA2 Gene MutationBreast CancerBreast Cancer InvasiveBreast Neoplasms

Phase 2

AR-inhibitor Bicalutamide in Treating Patients With TNBC

NCT02353988

Jinling Hospital, ChinaBreast Neoplasms

Start: 2015-01-31End: 2017-05-31Target: 60Updated: 2015-02-03

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

CompletedNCT03127215

National Center for Tumor Diseases, HeidelbergCancers With DNA Repair-Deficiency

Start: 2018-10-25End: 2023-12-19Updated: 2024-05-08

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

CompletedNCT03329690

Daiichi Sankyo Co., Ltd.Neoplasm, Gastrointestinal

Start: 2017-11-02End: 2020-12-11Updated: 2022-03-18

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruitingNCT04398914

Shanghai Jiao Tong University School of MedicineBreast Cancer Invasive

Start: 2020-05-30End: 2027-12-30Target: 216Updated: 2022-03-31

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

TerminatedNCT04488003

BioMed Valley Discoveries, IncAdvanced Solid Tumor, BRAF Gene Alteration, BRAF Gene Mutation +6

Start: 2021-01-07End: 2023-05-23Updated: 2024-06-04

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

RecruitingNCT06942442

Sarcoma Alliance for Research through CollaborationClear Cell Sarcoma (CCS), HLA-A*0201 Positive Cells Present

Start: 2025-10-22End: 2030-10-01Target: 47Updated: 2025-12-26

Phase 3

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

CompletedNCT00388726

Eisai Inc.Breast Cancer

Start: 2006-11-30End: 2013-06-30Updated: 2020-01-07

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

TerminatedNCT01905592

Tesaro, Inc.BRCA1 Gene Mutation, BRCA2 Gene Mutation, Carcinoma of Breast +3

Start: 2014-02-25End: 2021-10-26Updated: 2022-11-15

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

CompletedNCT03262935

Byondis B.V.Metastatic Breast Cancer

Start: 2017-12-15End: 2022-06-30Updated: 2023-10-19

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

RecruitingNCT05948475

TransThera Sciences (Nanjing), Inc.Cholangiocarcinoma

Start: 2023-12-20End: 2026-08-31Target: 200Updated: 2024-06-24

American Journal of Respiratory and Critical Care Medicine2025-05-01

Abstract 825: Correlation of clinical and biomarker data in FGFR inhibitor failed metastatic cholangiocarcinoma patients with tumor response to tinengotinib

Cancer Research2025-04-21

Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.

Journal of Clinical Oncology2025-01-271 citations

Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.

Journal of Clinical Oncology2024-06-01

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study

Breast Cancer Research and Treatment2024-04-064 citations

First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.

Journal of Clinical Oncology2024-01-205 citations

Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.

Journal of Clinical Oncology2023-06-01

Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).

Journal of Clinical Oncology2023-02-012 citations

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.

2022-08-1192 citations

Abstract 4022: ERK1/2 inhibitor ulixertinib demonstrates activity in atypical (non-V600) BRAF mutant models

Cancer Research2022-06-15

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).

Journal of Clinical Oncology2022-06-017 citations

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Journal of Clinical Oncology2022-01-1911 citations

Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.

Journal of Clinical Oncology2022-01-194 citations

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Journal of Clinical Oncology2021-05-2014 citations

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

Journal of Clinical Oncology2021-05-205 citations

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

New England Journal of Medicine2020-05-291212 citations

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).

Journal of Clinical Oncology2020-05-207 citations

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

Breast Cancer2020-03-0571 citations

Antibodies to watch in 2020.

2020-01-01328 citations

A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

Journal of Clinical Oncology2019-01-293 citations

11 more papers not shown

Physician's Choice

Sponsors

Conditions

Phase 2

Phase 3

Related Papers